Climb Bio Stock Performance
| CLYM Stock | 2.10 0.17 7.49% |
The firm shows a Beta (market volatility) of 0.33, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Climb Bio's returns are expected to increase less than the market. However, during the bear market, the loss of holding Climb Bio is expected to be smaller as well. At this point, Climb Bio has a negative expected return of -1.3%. Please make sure to confirm Climb Bio's maximum drawdown, as well as the relationship between the accumulation distribution and market facilitation index , to decide if Climb Bio performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Climb Bio has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Actual Historical Performance (%)
One Day Return (7.49) | Five Day Return 7.14 | Year To Date Return (73.18) | Ten Year Return (73.18) | All Time Return (73.18) |
1 | Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024 | 10/11/2024 |
2 | Insider Trading | 11/08/2024 |
3 | Acquisition by Williams Douglas E of 6291 shares of Climb Bio at 4.06 subject to Rule 16b-3 | 11/11/2024 |
4 | Climb Bio Inc. Shifts Focus to Immune-Mediated Diseases - TipRanks | 11/13/2024 |
5 | GitLab Shares Climb After Outlook Raise, Strong 3Q - MarketWatch | 12/06/2024 |
6 | Acquisition by Emily Pimblett of 5000 shares of Climb Bio subject to Rule 16b-3 | 12/18/2024 |
7 | Climb Bio set to join Nasdaq Biotech Index | 12/19/2024 |
Climb |
Climb Bio Relative Risk vs. Return Landscape
If you would invest 516.00 in Climb Bio on October 1, 2024 and sell it today you would lose (306.00) from holding Climb Bio or give up 59.3% of portfolio value over 90 days. Climb Bio is currently does not generate positive expected returns and assumes 4.7979% risk (volatility on return distribution) over the 90 days horizon. In different words, 42% of stocks are less volatile than Climb, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Climb Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Climb Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Climb Bio, and traders can use it to determine the average amount a Climb Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2716
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CLYM |
Estimated Market Risk
| 4.8 actual daily | 42 58% of assets are more volatile |
Expected Return
| -1.3 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.27 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Climb Bio is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Climb Bio by adding Climb Bio to a well-diversified portfolio.
Climb Bio Fundamentals Growth
Climb Stock prices reflect investors' perceptions of the future prospects and financial health of Climb Bio, and Climb Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Climb Stock performance.
| Net Income | (35.12 M) | ||||
| Total Debt | 2.87 M | ||||
| Total Asset | 110.47 M | ||||
| Retained Earnings | (155.98 M) | ||||
About Climb Bio Performance
By examining Climb Bio's fundamental ratios, stakeholders can obtain critical insights into Climb Bio's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Climb Bio is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Climb Bio is entity of United States. It is traded as Stock on NASDAQ exchange.Things to note about Climb Bio performance evaluation
Checking the ongoing alerts about Climb Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Climb Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Climb Bio generated a negative expected return over the last 90 days | |
| Climb Bio has high historical volatility and very poor performance | |
| Climb Bio has a very high chance of going through financial distress in the upcoming years | |
| Climb Bio was previously known as Eliem Therapeutics and was traded on NASDAQ Exchange under the symbol ELYM. | |
| Net Loss for the year was (35.12 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Latest headline from seekingalpha.com: Climb Bio set to join Nasdaq Biotech Index |
- Analyzing Climb Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Climb Bio's stock is overvalued or undervalued compared to its peers.
- Examining Climb Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Climb Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Climb Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Climb Bio's stock. These opinions can provide insight into Climb Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Climb Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Climb Bio. If investors know Climb will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Climb Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Climb Bio is measured differently than its book value, which is the value of Climb that is recorded on the company's balance sheet. Investors also form their own opinion of Climb Bio's value that differs from its market value or its book value, called intrinsic value, which is Climb Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Climb Bio's market value can be influenced by many factors that don't directly affect Climb Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Climb Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Climb Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Climb Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.